Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zynerba Pharmaceuticals, Inc. - Common Stock (NQ:ZYNE)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 10, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Zynerba Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Cannabis Stock Movers For July 10, 2023
Via Benzinga
Why Theriva Biologics Are Trading Higher By Over 76%; Here Are 20 Stocks Moving Premarket
Gainers Theriva Biologics, Inc. (NYSE: TOVX) shares surged 76.4% to $1.46 in pre-market trading after the company said Orphan Drug Designation was granted by the U.S. Food and Drug Administration for... 
Via Benzinga
Why American Equity Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 116 companies set new 52-week lows. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on Tuesday morning! 
Via InvestorPlace
Zynerba Pharmaceuticals R&D Expenses For Q1 Reach $7.1M, Here Are The Details
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) released financial results for the first quarter ended March 31, 2023, revealing research and development expenses were $7.1 million for the first quarter... 
Via Benzinga
Zynerba Pharmaceuticals R&D Expenses For FY22 Reach $21.1M, What About Net Loss?
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) released financial results for the fourth quarter and full year ended December 31, 2022, revealing research and development expenses were $21.1 million for... 
Via Benzinga
Silicon Valley Bank Failure Is Just The Tip Of Financial Iceberg, Could Affect Unexpected Industries
Last week the US economy got clobbered by the biggest banking collapse since 2008 when the parent of Silicon Valley Bank, SVB Financial Group (NASDAQ: SIVB) failed to raise enough capital to continue. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 345 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 497 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 135 companies reached new 52-week lows. 
Via Benzinga
ZYNE: Nano-Cap Company That Is Focused On Treatments For Neuropsychiatric Disorders
Given the progress of its clinical trials, and its latest quarterly financials, Zynerba appears to be an excellent buy-and-hold investment consideration. 
Via Talk Markets
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
What's The Role Of The Endocannabinoid System In Fragile X Syndrome? How Can Cannabidiol Treatment Help? New Paper
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), announced the publication of a paper entitled, “Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 258 companies hit new 52-week lows. 
Via Benzinga
CBD-Based Zygel Helps With Anxiety-Related & Behavioral Symptoms In 22q11.2 Deletion Syndrome, Phase 2 Trial Reveals
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) presented positive long-term 38-week data from the phase 2 INSPIRE trial with Zygel in children and adolescents with 22q11.2 deletion syndrome. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Cannabis Legalization In Germany And Thailand, Gray Market In Brooklyn, Craft Weed Companies In Oregon
German Opposition Official Against Recreational Marijuana Legalization Plan 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 70 companies set new 52-week lows. 
Via Benzinga
Zynerba Pharmaceuticals R&D Expenses For Q3 Reach $5M, Here Are The Details
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), released financial results for the third quarter ended September 30, 2022. Q3 2022 Financial Highlights 
Via Benzinga
A Comparison Of 5 Psychedelic ETFs And Indices
A look at 2 psychedelic ETFs and 3 tracking (non-trading) indices in the sector. 
Via Talk Markets
The Psychedelic Drug Stocks Index Continued To Plummet Last Week
In total, the Psychedelic Drug Stock Index went down 5.8% last week and is now down 64.9% YTD. 
Via Talk Markets
October Recap: Major Psychedelic Drug Stocks Declined 9.9%
In total, thePsychedelic Drug Stock Index went down 9.9% in September and is now down 64.7% YTD. 
Via Talk Markets
Cannabis Category Performances Ranged From +14.4% To -4.6% This Past Week
The 5 categories in the cannabis sector perform quite differently week to week. Below is a summary of how each category performed last week, in descending order and since the end of September and since... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.